Ascendis Pharma A/S (ASND)
228.03
+0.16
(+0.07%)
USD |
NASDAQ |
Oct 05, 16:00
228.35
+0.32
(+0.14%)
After-Hours: 20:00
Ascendis Pharma Price to Book Value : 9.118 for Oct. 5, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 9.118 |
| October 02, 2026 | 9.112 |
| October 01, 2026 | 9.090 |
| September 30, 2026 | 9.110 |
| September 29, 2026 | 9.12 |
| September 28, 2026 | 9.199 |
| September 25, 2026 | 9.021 |
| September 24, 2026 | 9.225 |
| September 23, 2026 | 8.922 |
| September 22, 2026 | 9.500 |
| September 21, 2026 | 9.501 |
| September 18, 2026 | 9.466 |
| September 17, 2026 | 9.559 |
| September 16, 2026 | 9.904 |
| September 15, 2026 | 9.588 |
| September 14, 2026 | 10.59 |
| September 11, 2026 | 10.54 |
| September 10, 2026 | 10.45 |
| September 09, 2026 | 10.43 |
| September 08, 2026 | 10.80 |
| September 04, 2026 | 10.82 |
| September 03, 2026 | 10.84 |
| September 02, 2026 | 10.69 |
| September 01, 2026 | 10.41 |
| August 31, 2026 | 10.52 |
| Date | Value |
|---|---|
| August 28, 2026 | 9.913 |
| August 27, 2026 | 9.971 |
| August 26, 2026 | 10.01 |
| August 25, 2026 | 10.12 |
| August 24, 2026 | 10.07 |
| August 21, 2026 | 10.13 |
| August 20, 2026 | 10.19 |
| August 19, 2026 | 10.38 |
| August 18, 2026 | 9.951 |
| August 17, 2026 | 9.893 |
| August 14, 2026 | 9.937 |
| August 13, 2026 | 9.846 |
| August 12, 2026 | 10.22 |
| August 11, 2026 | 10.18 |
| August 10, 2026 | 10.22 |
| August 07, 2026 | 10.21 |
| August 06, 2026 | 9.991 |
| August 05, 2026 | 9.765 |
| August 04, 2026 | 9.781 |
| August 03, 2026 | 9.735 |
| July 31, 2026 | 9.753 |
| July 30, 2026 | 10.04 |
| July 29, 2026 | 10.08 |
| July 28, 2026 | 10.17 |
| July 27, 2026 | 10.13 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.762 |
| Novo Nordisk A/S | 4.903 |
| Evaxion AS | 2.756 |
| Genmab A/S | 3.856 |
| Zealand Pharma A/S | 1.014 |
Price to Book Value Related Metrics
| PE Ratio | 17.37 |
| PS Ratio | 11.91 |
| Price to Free Cash Flow | 37.38 |
| Price | 228.03 |
| Earnings Yield | 5.76% |
| Market Cap | 14.98B |
| Operating PE Ratio | 115.41 |
| Normalized PE Ratio | 17.37 |